Mauna Kea Technologies SAS (MKEA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mauna Kea Technologies SAS (MKEA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3446
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicroscopy platform that provides microscopic images of tissue instantaneously and in a minimally-invasive way. The company also offers vasculature and vasodynamics studies, longitudinal monitoring of disease progression and in vivo histology. It provides technical support and training. MKT’s products are used for treatment of digestive diseases and diagnosing respiratory diseases and also used in laboratories for research on small animals. The company has presence in North America, Europe and Asia. MKT is headquartered in Paris, France.

Mauna Kea Technologies SAS (MKEA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Mauna Kea Technologies SAS, Medical Devices Deals, 2012 to YTD 2018 9
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Mauna Kea Technologies to Raise USD9.1 Million in Public Offering of Shares 11
Mauna Kea Technologies to Raise USD5.7 Million in Public Offering of Shares 12
Debt Offering 13
Mauna Kea Tech Raises USD4.3 Million in First Tranche of Private Placement of Bonds Due 2022 13
Mauna Kea Technologies SAS – Key Competitors 14
Mauna Kea Technologies SAS – Key Employees 15
Mauna Kea Technologies SAS – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Sep 20, 2017: Mauna Kea Technologies Reports First Half 2017 Financial Results 17
Jul 25, 2017: Mauna Kea Technologies Reports First Half 2017 Sales 19
Apr 19, 2017: Mauna Kea Technologies Reports First Quarter 2017 Sales 20
Mar 23, 2017: Mauna Kea Technologies Reports Full Year 2016 Financial Results And Highlights 2017 Key Priorities 21
Jan 24, 2017: Mauna Kea Technologies Reports Fourth Quarter and Full Year 2016 Sales 23
Corporate Communications 24
Apr 05, 2018: Appointment of Christophe Lamboeuf to the position of Chief Financial Officer 24
Jan 15, 2018: Mauna Kea Technologies Appoints Experienced Healthcare Executive, Molly O’Neill, to Board of Directors 25
Oct 17, 2017: Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial Officer 26
Mar 13, 2017: Mauna Kea Appoints Jennifer F. Tseng, M.D. to Board of Directors 27
Other Significant Developments 28
Jul 25, 2018: Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mauna Kea Technologies SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Mauna Kea Technologies SAS, Medical Devices Deals, 2012 to YTD 2018 9
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mauna Kea Technologies to Raise USD9.1 Million in Public Offering of Shares 11
Mauna Kea Technologies to Raise USD5.7 Million in Public Offering of Shares 12
Mauna Kea Tech Raises USD4.3 Million in First Tranche of Private Placement of Bonds Due 2022 13
Mauna Kea Technologies SAS, Key Competitors 14
Mauna Kea Technologies SAS, Key Employees 15
Mauna Kea Technologies SAS, Subsidiaries 16

List of Figures
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mauna Kea Technologies SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Mauna Kea Technologies SAS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Mauna Kea Technologies SAS (MKEA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Oasis Diagnostics Corp:企業の製品パイプライン分析2018
    Summary Oasis Diagnostics Corp (Oasis Diagnostics) is a medical device company that develops and commercializes tools for non-invasive diagnosis and detection of diseases. The company's products include saliva DNA isolation kit, genomic kit and immunoassay products, among others. Its saliva DNA isol …
  • Artios Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Artios Pharma Ltd (Artios Pharma) is an independent company that focuses on the development of DNA Damage Response (DDR) therapies to treat cancer. The company has in-licensed its lead DDR programme, DNA polymerase theta (PolO) from Cancer Research Technology (CRT), which target proteins tha …
  • Asian Citrus Holdings Ltd (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • National Gas & Industrial Co (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Adapt Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Adapt Pharma Ltd (Adapt Pharma) is a drug discovery and development company that manufactures and distributes prescription medicines. The company’s product Narcan (naloxone hydrochloride) nasal spray is an opioid antagonist that is indicated for the emergency treatment of opioid overdose as …
  • Ernst & Young Global Ltd:企業の戦略・SWOT・財務情報
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • MEG Energy Corp (MEG):石油・ガス:M&Aディール及び事業提携情報
    Summary MEG Energy Corp (MEG) is an oil and gas company that develops and produces from oil sands. The company operates Christina lake, May River and Surmont project. Its technologies comprise steam-assisted gravity drainage, cogeneration, Hi-Q field pilot and eMSAGP. MEG's Christina Lake project is …
  • Energisa SA (ENGI11):企業の財務・戦略的SWOT分析
    Energisa SA (ENGI11) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NeoDynamics AB:製品パイプライン分析
    Summary NeoDynamics AB (NeoDynamics) is an independent medical technology company that focuses on the development of medical solutions for the quick detection and treatment of cancer. It is developing the NeoNavia biopsy system that helps collect samples from breast lesions or axillary lymph nodes f …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Reed’s, Inc.:企業の戦略・SWOT・財務分析
    Reed's, Inc. - Strategy, SWOT and Corporate Finance Report Summary Reed's, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Total SA (FP):石油・ガス:M&Aディール及び事業提携情報
    Summary Total SA (Total) is an integrated global energy company that discovers, produces, refines and markets oil and gas, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distributio …
  • SIGVARIS Management AG:企業の戦略的SWOT分析
    SIGVARIS Management AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Chubb European Group SE:企業の戦略的SWOT分析
    Chubb European Group SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Avantec Vascular Corp:製品パイプライン分析
    Summary Avantec Vascular Corp (Avantec Vascular), a subsidiary of Goodman Co Ltd is a medical device company that develops cardiovascular interventional and peripheral vascular devices. The company's products comprise balloon catheter, aspiration catheter, device delivery system, micro catheter, gui …
  • Unibail-Rodamco-Westfield Se:企業の戦略・SWOT・財務分析
    Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report Summary Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Fujikoh Company Ltd-エネルギー分野:企業M&A・提携分析
    Summary Fujikoh Company Ltd (Fujikoh Company) is a clean technology company that offers waste recycling services. The company provides biomass and environmental recycling services. It offers construction waste recycling, waste food recycling and termite dismantling and demolition services. Fujikoh C …
  • Anworth Mortgage Asset Corp (ANH):企業の財務・戦略的SWOT分析
    Summary Anworth Mortgage Asset Corp (Anworth) is a financial service provider that provides mortgage real estate investment services. The company invests in mortgage-backed securities on a leveraged basis. It operates through agency credit-backed securities and non-agency credit-backed securities. A …
  • Intraco Ltd (I06):企業の財務・戦略的SWOT分析
    Intraco Ltd (I06) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆